A very low number of circulating basophils is predictive of a poor response to omalizumab in chronic spontaneous urticaria
暂无分享,去创建一个
P. Korošec | M. Košnik | M. Rijavec | M. Zidarn | M. Bizjak | A. Koren | P. Kopač | J. Šelb | Romana Vantur | Nissera Bajrovič | Žan Kogovšek
[1] M. Rovaris,et al. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.
[2] T. Zuberbier,et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria , 2018, Allergy.
[3] D. Larenas-Linnemann,et al. Update on Omalizumab for Urticaria: What’s New in the Literature from Mechanisms to Clinic , 2018, Current Allergy and Asthma Reports.
[4] C. Möbs,et al. Functional and phenotypic analysis of basophils allows determining distinct subtypes in patients with chronic urticaria , 2017, Allergy.
[5] P. Korošec,et al. Basophils, high-affinity IgE receptors, and CCL2 in human anaphylaxis , 2017, The Journal of allergy and clinical immunology.
[6] A. Giménez-Arnau,et al. Basophil FcεRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab Therapy. , 2017, Acta dermato-venereologica.
[7] T. Omachi,et al. Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria. , 2017, The Journal of investigative dermatology.
[8] A. Giménez-Arnau,et al. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria , 2017, Allergy.
[9] M. Lawrence,et al. Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria. , 2016, The journal of allergy and clinical immunology. In practice.